Skip to main content
. 2021 Nov 5;81(2):184–192. doi: 10.1136/annrheumdis-2021-221051

Table 4.

Common TEAEs (≥3% in any treatment group) in the PBO-controlled period up to week 12

FIL 200 mg
N=777
FIL 100 mg
N=788
PBO
N=781
Nasopharyngitis, n (%) 27 (3.5) 19 (2.4) 19 (2.4)
Upper respiratory tract infection, n (%) 26 (3.3) 20 (2.5) 14 (1.8)
Nausea, n (%) 27 (3.5) 18 (2.3) 13 (1.7)

FIL, filgotinib; PBO, placebo; TEAE, treatment-emergent adverse event.